NDRG4 and colorectal carcinoma: At present, three methylation biomarkers—NDRG4, BMP3, and SEPT9-have received Food and Drug Administration (FDA) approval for CRC screening, representing the inaugural endorsement of a fecal-based multitarget group for such screening [76].